Sulbactam

Manufactured by Pfizer

Sourced in United States

Sulbactam is a beta-lactamase inhibitor that is used in combination with other antibiotics to treat certain bacterial infections. It functions by blocking the action of enzymes produced by bacteria that can break down and inactivate certain antibiotics, allowing the antibiotic to be more effective.

Automatically generated - may contain errors

Lab products found in correlation

Cefoperazone, by Pfizer (2 mentions) Ampicillin, by Merck Group (1 mentions) Clavulanic acid, by Merck Group (1 mentions) Nitrocefin, by BD (1 mentions) Cephalothin, by Merck Group (1 mentions) Tazobactam, by Chem-Impex (1 mentions) Securestrap, by Johnson & Johnson (1 mentions) Vypro, by Johnson & Johnson (1 mentions) Ultrapro, by Johnson & Johnson (1 mentions) Prolene, by Johnson & Johnson (1 mentions) Cefoperazone sulbactam, by Pfizer (1 mentions)

Spelling variants of this product

Ampicillin/sulbactam (8 citations) Cefoperazone/sulbactam (7 citations) Cefoperazone/sulbactam sodium (2 citations)

4 protocols using sulbactam

Synthesis and Characterization of β-Lactamase Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

The antibiotics
used in this study were obtained from their respective manufacturers
as indicated: ampicillin, cephalothin, and clavulanic acid, potassium
salt, from Sigma (St. Louis, MO); sulbactam, sodium salt, from Pfizer
(Groton, CT); tazobactam, sodium salt, from Chem-IMPEX (Wood Dale,
IL); and nitrocefin from Becton Dickinson (Franklin Lakes, NJ). The
sodium salt of PSR-3-283A (263 Da) and 6-D,D-sulbactam were synthesized
in the laboratory of John D. Buynak. Chemical structures of β-lactamase
inhibitors are represented in Figure 1.

Che T., Rodkey E.A., Bethel C.R., Shanmugam S., Ding Z., Pusztai-Carey M., Nottingham M., Chai W., Buynak J.D., Bonomo R.A., van den Akker F, & Carey P.R. (2014). Detecting a Quasi-stable Imine Species on the Reaction Pathway of SHV-1 β-Lactamase and 6β-(Hydroxymethyl)penicillanic Acid Sulfone. Biochemistry, 54(3), 734-743.

+ Open protocol

+ Expand

Hernia Repair Techniques and Mesh Types

Check if the same lab product or an alternative is used in the 5 most similar protocols

Inguinal/femoral hernias were repaired either by open (Lichtenstein) or minimally invasive techniques, that is totally extraperitoneal (TEP) or transabdominal preperitoneal (TAPP). Preoperatively, 2 g ampicillin/1 g sulbactam (Pfizer, Berlin, Germany) was given for Lichtenstein, but not for minimally invasive repair. Partially absorbable lightweight polypropylene-polyglecaprone mesh (ULTRAPRO, Ethicon, Norderstedt, Germany) was cropped to 15 × 12 cm for augmentation.
Same antibiotic was pre-operatively given for ventral, incisional and parastomal hernia repairs. Between 2001 and 2012, we implanted lightweight polypropylene-polyglactin mesh (Vypro, Ethicon, Norderstedt, Germany) during open repair. Afterwards, we switched to a lightweight polypropylene mesh (Optilene, Braun, Melsungen, Germany). The meshes were routinely positioned retromuscularly with minimum 5 cm overlap of the fascial defect and fixed with interrupted 2/0 polypropylene sutures (Prolene, Ethicon, Norderstedt, Germany). During minimally invasive intraperitoneal onlay mesh (IPOM), a non-absorbable polypropylene mesh (Proceed, Ethicon, Norderstedt, Germany) was fixed with four 2/0 polypropylene sutures (Prolene, Ethicon, Norderstedt, Germany) and absorbable tacks (Securestrap, Ethicon, Norderstedt, Germany) in double crown technique.

Lee L.D., Stroux A., Nickisch D., Wröbel L., Aschenbrenner K., Weixler B., Kreis M.E, & Lauscher J.C. (2020). Operative outcome of hernia repair with synthetic mesh in immunocompromised patients. ANZ journal of surgery, 90(11).

+ Open protocol

+ Expand

Pharmacokinetics of Cefoperazone/Sulbactam

Check if the same lab product or an alternative is used in the 5 most similar protocols

cefoperazone/sulbactam (Sulperazon, Pfizer, New York, USA) in 1.5-g ampoules with cefoperazone 1.0 g/sulbactam 0.5g was given to all included patients. All the patients were given cefoperazone/sulbactam 3.0 g in 50-mL saline by intravenous injection for 3 hours every 6 hours after craniotomy. 1.5mL of venous blood and 1.5 mL of CSF were collected before the start of drug administration and at Hour 1, 2, 3, 4, 6, 12, 15, 16, 18 h after administration. The specimens were centrifuged at a speed of 3500 r/min for 5 min. Then, the supernatant was collected and stored at −70°C for uniform testing.

Wang Q., Wu Y., Chen B, & Zhou J. (2015). Drug concentrations in the serum and cerebrospinal fluid of patients treated with cefoperazone/sulbactam after craniotomy. BMC Anesthesiology, 15, 33.

+ Open protocol

+ Expand

Combination Therapy for Pan-resistant Acinetobacter baumannii

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The extracted pan-resistant Acinetobacter baumannii was observed immediately and was divided into colonized bacteria and infectious bacteria according to the hospital infection diagnostic criteria established by the Ministry of Health. The extracted bacterium was defined as colonized bacteria if it did not qualify for the diagnostic criteria (6 (link)).
The treatment effects of groups A and B were retrospectively analyzed. The antibacterial drugs employed in group A were a combination of cefoperazone, sulbactam (Pfizer, NY, USA) and tanreqing (Kangbao, Shanxi, China). cefoperazone (2 g) and sulbactam (3 g) were administered by intravenous drip every 8 h. Tanreqing (20 ml) was then added into the intravenous drip once a day. For group B, the cases were treated with only cefoperazone and sulbactam. The curative effect and prognosis of the two groups were recorded and the remaining treatments were administered as per clinical routine. The effects were evaluated based on the guiding principles of clinical research on antibacterial agents, as established released by the Ministry of Health (7 (link)). The main criteria for the clinical effects were symptom, sign and laboratory inspection. The 4 grades for assessment were: recovery, significantly improved, improved and no response. In addition, mortality within 28 days after infection was observed.

PAN T., LIU X., XIANG S, & JI W. (2016). Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection. Experimental and Therapeutic Medicine, 11(4), 1345-1347.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!